nodes	percent_of_prediction	percent_of_DWPC	metapath
Sibutramine—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—ALDH2—esophageal cancer	0.0111	0.058	CbGpPWpGaD
Sibutramine—SLC6A3—Alpha-synuclein signaling—UCHL1—esophageal cancer	0.00655	0.0342	CbGpPWpGaD
Sibutramine—SLC6A3—Alpha-synuclein signaling—FKBP1A—esophageal cancer	0.00623	0.0325	CbGpPWpGaD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—UCHL1—esophageal cancer	0.00556	0.029	CbGpPWpGaD
Sibutramine—SLC6A3—Dopaminergic Neurogenesis—SOX2—esophageal cancer	0.00422	0.022	CbGpPWpGaD
Sibutramine—CYP3A4—Codeine and Morphine Metabolism—ABCC2—esophageal cancer	0.004	0.0209	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—ALDH3A1—esophageal cancer	0.00359	0.0187	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—BLVRB—esophageal cancer	0.0032	0.0167	CbGpPWpGaD
Sibutramine—CYP3A4—Fatty Acid Omega Oxidation—ADH7—esophageal cancer	0.00316	0.0165	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—ALDH3A1—esophageal cancer	0.00309	0.0161	CbGpPWpGaD
Sibutramine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A6—esophageal cancer	0.00289	0.0151	CbGpPWpGaD
Sibutramine—CYP3A4—Tryptophan metabolism—ALDH3A2—esophageal cancer	0.00278	0.0145	CbGpPWpGaD
Sibutramine—CYP3A4—Fatty Acid Omega Oxidation—ADH1B—esophageal cancer	0.00277	0.0145	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—BLVRB—esophageal cancer	0.00275	0.0144	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—ALDH3A1—esophageal cancer	0.00273	0.0143	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—PRDX1—esophageal cancer	0.00272	0.0142	CbGpPWpGaD
Sibutramine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A7—esophageal cancer	0.00264	0.0138	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—ADCYAP1—esophageal cancer	0.00258	0.0135	CbGpPWpGaD
Sibutramine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A6—esophageal cancer	0.00256	0.0134	CbGpPWpGaD
Sibutramine—CYP3A4—Irinotecan Pathway—ABCC2—esophageal cancer	0.00256	0.0134	CbGpPWpGaD
Sibutramine—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—esophageal cancer	0.00246	0.0128	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—BLVRB—esophageal cancer	0.00244	0.0127	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—SLC39A6—esophageal cancer	0.00242	0.0127	CbGpPWpGaD
Sibutramine—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—esophageal cancer	0.00235	0.0123	CbGpPWpGaD
Sibutramine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A7—esophageal cancer	0.00234	0.0122	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—PRDX1—esophageal cancer	0.00234	0.0122	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—ADH7—esophageal cancer	0.00231	0.0121	CbGpPWpGaD
Sibutramine—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC2—esophageal cancer	0.00219	0.0114	CbGpPWpGaD
Sibutramine—CYP3A4—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.00212	0.0111	CbGpPWpGaD
Sibutramine—Arthritis—Capecitabine—esophageal cancer	0.00212	0.00262	CcSEcCtD
Sibutramine—Renal failure—Cisplatin—esophageal cancer	0.00211	0.00261	CcSEcCtD
Sibutramine—Myocardial infarction—Cisplatin—esophageal cancer	0.00211	0.00261	CcSEcCtD
Sibutramine—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00211	0.00261	CcSEcCtD
Sibutramine—SLC6A4—Circadian rythm related genes—CRTC1—esophageal cancer	0.00211	0.011	CbGpPWpGaD
Sibutramine—Cerebrovascular accident—Capecitabine—esophageal cancer	0.0021	0.00259	CcSEcCtD
Sibutramine—Stomatitis—Cisplatin—esophageal cancer	0.00209	0.00259	CcSEcCtD
Sibutramine—Conjunctivitis—Cisplatin—esophageal cancer	0.00209	0.00258	CcSEcCtD
Sibutramine—SLC6A2—NRF2 pathway—SLC39A6—esophageal cancer	0.00209	0.0109	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—PRDX1—esophageal cancer	0.00207	0.0108	CbGpPWpGaD
Sibutramine—Cystitis noninfective—Methotrexate—esophageal cancer	0.00206	0.00255	CcSEcCtD
Sibutramine—Osteoarthritis—Capecitabine—esophageal cancer	0.00206	0.00254	CcSEcCtD
Sibutramine—Pain in extremity—Capecitabine—esophageal cancer	0.00206	0.00254	CcSEcCtD
Sibutramine—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00206	0.00254	CcSEcCtD
Sibutramine—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00204	0.00252	CcSEcCtD
Sibutramine—Cystitis—Methotrexate—esophageal cancer	0.00204	0.00252	CcSEcCtD
Sibutramine—Migraine—Capecitabine—esophageal cancer	0.00202	0.0025	CcSEcCtD
Sibutramine—SLC6A2—NRF2 pathway—ADH7—esophageal cancer	0.00199	0.0104	CbGpPWpGaD
Sibutramine—Face oedema—Capecitabine—esophageal cancer	0.00198	0.00245	CcSEcCtD
Sibutramine—Bradycardia—Cisplatin—esophageal cancer	0.00196	0.00243	CcSEcCtD
Sibutramine—CYP3A4—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.00195	0.0102	CbGpPWpGaD
Sibutramine—Urinary retention—Capecitabine—esophageal cancer	0.00195	0.00242	CcSEcCtD
Sibutramine—Cardiac arrest—Capecitabine—esophageal cancer	0.00195	0.00242	CcSEcCtD
Sibutramine—Mood swings—Capecitabine—esophageal cancer	0.00195	0.00241	CcSEcCtD
Sibutramine—Ataxia—Capecitabine—esophageal cancer	0.00193	0.00239	CcSEcCtD
Sibutramine—Blood creatinine increased—Capecitabine—esophageal cancer	0.00193	0.00238	CcSEcCtD
Sibutramine—Dehydration—Capecitabine—esophageal cancer	0.00191	0.00236	CcSEcCtD
Sibutramine—Ecchymosis—Methotrexate—esophageal cancer	0.00191	0.00236	CcSEcCtD
Sibutramine—Bladder pain—Methotrexate—esophageal cancer	0.00191	0.00236	CcSEcCtD
Sibutramine—Neoplasm—Methotrexate—esophageal cancer	0.00191	0.00236	CcSEcCtD
Sibutramine—Mouth ulceration—Methotrexate—esophageal cancer	0.00191	0.00236	CcSEcCtD
Sibutramine—Liver function test abnormal—Capecitabine—esophageal cancer	0.0019	0.00235	CcSEcCtD
Sibutramine—Dry skin—Capecitabine—esophageal cancer	0.00188	0.00233	CcSEcCtD
Sibutramine—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00188	0.00232	CcSEcCtD
Sibutramine—Hypokalaemia—Capecitabine—esophageal cancer	0.00187	0.00231	CcSEcCtD
Sibutramine—Visual impairment—Cisplatin—esophageal cancer	0.00186	0.0023	CcSEcCtD
Sibutramine—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.00185	0.00229	CcSEcCtD
Sibutramine—SLC6A3—NRF2 pathway—SLC39A6—esophageal cancer	0.00185	0.00964	CbGpPWpGaD
Sibutramine—CYP3A4—Fatty Acid Omega Oxidation—CYP2A6—esophageal cancer	0.00184	0.00959	CbGpPWpGaD
Sibutramine—Sepsis—Methotrexate—esophageal cancer	0.00183	0.00226	CcSEcCtD
Sibutramine—Gastritis—Capecitabine—esophageal cancer	0.00182	0.00225	CcSEcCtD
Sibutramine—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00181	0.00224	CcSEcCtD
Sibutramine—Muscular weakness—Capecitabine—esophageal cancer	0.00181	0.00224	CcSEcCtD
Sibutramine—Eye disorder—Cisplatin—esophageal cancer	0.0018	0.00223	CcSEcCtD
Sibutramine—Tinnitus—Cisplatin—esophageal cancer	0.0018	0.00222	CcSEcCtD
Sibutramine—Lymphadenopathy—Methotrexate—esophageal cancer	0.00179	0.00222	CcSEcCtD
Sibutramine—Abdominal distension—Capecitabine—esophageal cancer	0.00179	0.00221	CcSEcCtD
Sibutramine—Influenza—Capecitabine—esophageal cancer	0.00178	0.0022	CcSEcCtD
Sibutramine—Dysphagia—Capecitabine—esophageal cancer	0.00178	0.0022	CcSEcCtD
Sibutramine—Asthma—Capecitabine—esophageal cancer	0.00178	0.0022	CcSEcCtD
Sibutramine—SLC6A3—NRF2 pathway—ADH7—esophageal cancer	0.00176	0.0092	CbGpPWpGaD
Sibutramine—Diabetes mellitus—Methotrexate—esophageal cancer	0.00176	0.00218	CcSEcCtD
Sibutramine—Photosensitivity—Methotrexate—esophageal cancer	0.00174	0.00216	CcSEcCtD
Sibutramine—Immune system disorder—Cisplatin—esophageal cancer	0.00174	0.00216	CcSEcCtD
Sibutramine—Angina pectoris—Capecitabine—esophageal cancer	0.00173	0.00214	CcSEcCtD
Sibutramine—Arrhythmia—Cisplatin—esophageal cancer	0.00172	0.00213	CcSEcCtD
Sibutramine—Bronchitis—Capecitabine—esophageal cancer	0.00171	0.00211	CcSEcCtD
Sibutramine—Alopecia—Cisplatin—esophageal cancer	0.0017	0.00211	CcSEcCtD
Sibutramine—SLC6A4—NRF2 pathway—ABCC2—esophageal cancer	0.00168	0.00877	CbGpPWpGaD
Sibutramine—Malnutrition—Cisplatin—esophageal cancer	0.00168	0.00208	CcSEcCtD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—RUNX3—esophageal cancer	0.00166	0.00868	CbGpPWpGaD
Sibutramine—Dysuria—Capecitabine—esophageal cancer	0.00166	0.00205	CcSEcCtD
Sibutramine—Flatulence—Cisplatin—esophageal cancer	0.00165	0.00205	CcSEcCtD
Sibutramine—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00162	0.00201	CcSEcCtD
Sibutramine—Weight increased—Capecitabine—esophageal cancer	0.00162	0.002	CcSEcCtD
Sibutramine—Muscle spasms—Cisplatin—esophageal cancer	0.00161	0.002	CcSEcCtD
Sibutramine—Hyperglycaemia—Capecitabine—esophageal cancer	0.0016	0.00198	CcSEcCtD
Sibutramine—Pneumonia—Capecitabine—esophageal cancer	0.00159	0.00197	CcSEcCtD
Sibutramine—Vision blurred—Cisplatin—esophageal cancer	0.00158	0.00196	CcSEcCtD
Sibutramine—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.00158	0.00196	CcSEcCtD
Sibutramine—Depression—Capecitabine—esophageal cancer	0.00158	0.00195	CcSEcCtD
Sibutramine—Tremor—Cisplatin—esophageal cancer	0.00157	0.00195	CcSEcCtD
Sibutramine—SLC6A4—NRF2 pathway—NFE2L2—esophageal cancer	0.00156	0.00816	CbGpPWpGaD
Sibutramine—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00156	0.00193	CcSEcCtD
Sibutramine—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00156	0.00193	CcSEcCtD
Sibutramine—Ill-defined disorder—Cisplatin—esophageal cancer	0.00156	0.00193	CcSEcCtD
Sibutramine—Renal failure—Capecitabine—esophageal cancer	0.00156	0.00193	CcSEcCtD
Sibutramine—Myocardial infarction—Capecitabine—esophageal cancer	0.00155	0.00192	CcSEcCtD
Sibutramine—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00155	0.00192	CcSEcCtD
Sibutramine—Anaemia—Cisplatin—esophageal cancer	0.00155	0.00192	CcSEcCtD
Sibutramine—Stomatitis—Capecitabine—esophageal cancer	0.00154	0.00191	CcSEcCtD
Sibutramine—Conjunctivitis—Capecitabine—esophageal cancer	0.00154	0.0019	CcSEcCtD
Sibutramine—Urinary tract infection—Capecitabine—esophageal cancer	0.00154	0.0019	CcSEcCtD
Sibutramine—CYP3A4—Xenobiotics—CYP2A6—esophageal cancer	0.00154	0.00803	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—GAPDH—esophageal cancer	0.00153	0.00801	CbGpPWpGaD
Sibutramine—Osteoarthritis—Methotrexate—esophageal cancer	0.00153	0.00189	CcSEcCtD
Sibutramine—Malaise—Cisplatin—esophageal cancer	0.00151	0.00187	CcSEcCtD
Sibutramine—Haematuria—Capecitabine—esophageal cancer	0.00151	0.00187	CcSEcCtD
Sibutramine—Leukopenia—Cisplatin—esophageal cancer	0.0015	0.00186	CcSEcCtD
Sibutramine—Epistaxis—Capecitabine—esophageal cancer	0.00149	0.00185	CcSEcCtD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—SOX2—esophageal cancer	0.00148	0.00773	CbGpPWpGaD
Sibutramine—CYP3A4—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00148	0.00772	CbGpPWpGaD
Sibutramine—Convulsion—Cisplatin—esophageal cancer	0.00146	0.0018	CcSEcCtD
Sibutramine—Mood swings—Methotrexate—esophageal cancer	0.00145	0.00179	CcSEcCtD
Sibutramine—Bradycardia—Capecitabine—esophageal cancer	0.00145	0.00179	CcSEcCtD
Sibutramine—SLC6A2—NRF2 pathway—ABCC2—esophageal cancer	0.00145	0.00754	CbGpPWpGaD
Sibutramine—Ataxia—Methotrexate—esophageal cancer	0.00144	0.00178	CcSEcCtD
Sibutramine—Myalgia—Cisplatin—esophageal cancer	0.00143	0.00177	CcSEcCtD
Sibutramine—Haemoglobin—Capecitabine—esophageal cancer	0.00143	0.00177	CcSEcCtD
Sibutramine—Rhinitis—Capecitabine—esophageal cancer	0.00143	0.00176	CcSEcCtD
Sibutramine—Anxiety—Cisplatin—esophageal cancer	0.00142	0.00176	CcSEcCtD
Sibutramine—Haemorrhage—Capecitabine—esophageal cancer	0.00142	0.00176	CcSEcCtD
Sibutramine—Hypoaesthesia—Capecitabine—esophageal cancer	0.00141	0.00175	CcSEcCtD
Sibutramine—Liver function test abnormal—Methotrexate—esophageal cancer	0.00141	0.00175	CcSEcCtD
Sibutramine—Discomfort—Cisplatin—esophageal cancer	0.00141	0.00175	CcSEcCtD
Sibutramine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.00141	0.00737	CbGpPWpGaD
Sibutramine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.00141	0.00737	CbGpPWpGaD
Sibutramine—Pharyngitis—Capecitabine—esophageal cancer	0.00141	0.00175	CcSEcCtD
Sibutramine—Oedema peripheral—Capecitabine—esophageal cancer	0.0014	0.00173	CcSEcCtD
Sibutramine—Anaphylactic shock—Cisplatin—esophageal cancer	0.00137	0.0017	CcSEcCtD
Sibutramine—Oedema—Cisplatin—esophageal cancer	0.00137	0.0017	CcSEcCtD
Sibutramine—Visual impairment—Capecitabine—esophageal cancer	0.00137	0.0017	CcSEcCtD
Sibutramine—Infection—Cisplatin—esophageal cancer	0.00136	0.00168	CcSEcCtD
Sibutramine—CYP3A4—Estrogen metabolism—CYP1B1—esophageal cancer	0.00135	0.00704	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—NFE2L2—esophageal cancer	0.00134	0.00701	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—CYP2A6—esophageal cancer	0.00134	0.00701	CbGpPWpGaD
Sibutramine—Thrombocytopenia—Cisplatin—esophageal cancer	0.00134	0.00166	CcSEcCtD
Sibutramine—Tachycardia—Cisplatin—esophageal cancer	0.00134	0.00165	CcSEcCtD
Sibutramine—Skin disorder—Cisplatin—esophageal cancer	0.00133	0.00165	CcSEcCtD
Sibutramine—Eye disorder—Capecitabine—esophageal cancer	0.00133	0.00164	CcSEcCtD
Sibutramine—Tinnitus—Capecitabine—esophageal cancer	0.00133	0.00164	CcSEcCtD
Sibutramine—Hyperhidrosis—Cisplatin—esophageal cancer	0.00132	0.00164	CcSEcCtD
Sibutramine—Asthma—Methotrexate—esophageal cancer	0.00132	0.00164	CcSEcCtD
Sibutramine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.00132	0.00689	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.00131	0.00686	CbGpPWpGaD
Sibutramine—Eosinophilia—Methotrexate—esophageal cancer	0.00131	0.00162	CcSEcCtD
Sibutramine—Anorexia—Cisplatin—esophageal cancer	0.00131	0.00162	CcSEcCtD
Sibutramine—Angiopathy—Capecitabine—esophageal cancer	0.00129	0.0016	CcSEcCtD
Sibutramine—Immune system disorder—Capecitabine—esophageal cancer	0.00128	0.00159	CcSEcCtD
Sibutramine—Hypotension—Cisplatin—esophageal cancer	0.00128	0.00158	CcSEcCtD
Sibutramine—SLC6A3—NRF2 pathway—ABCC2—esophageal cancer	0.00128	0.00668	CbGpPWpGaD
Sibutramine—Chills—Capecitabine—esophageal cancer	0.00128	0.00158	CcSEcCtD
Sibutramine—Arrhythmia—Capecitabine—esophageal cancer	0.00127	0.00157	CcSEcCtD
Sibutramine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.00126	0.00657	CbGpPWpGaD
Sibutramine—Alopecia—Capecitabine—esophageal cancer	0.00126	0.00155	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00125	0.00154	CcSEcCtD
Sibutramine—Malnutrition—Capecitabine—esophageal cancer	0.00124	0.00153	CcSEcCtD
Sibutramine—Dysuria—Methotrexate—esophageal cancer	0.00124	0.00153	CcSEcCtD
Sibutramine—Paraesthesia—Cisplatin—esophageal cancer	0.00123	0.00152	CcSEcCtD
Sibutramine—Dyspnoea—Cisplatin—esophageal cancer	0.00122	0.00151	CcSEcCtD
Sibutramine—Flatulence—Capecitabine—esophageal cancer	0.00122	0.00151	CcSEcCtD
Sibutramine—Erectile dysfunction—Methotrexate—esophageal cancer	0.00122	0.00151	CcSEcCtD
Sibutramine—Dysgeusia—Capecitabine—esophageal cancer	0.00121	0.0015	CcSEcCtD
Sibutramine—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00121	0.00149	CcSEcCtD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.0012	0.00627	CbGpPWpGaD
Sibutramine—Back pain—Capecitabine—esophageal cancer	0.0012	0.00148	CcSEcCtD
Sibutramine—CYP3A4—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00119	0.00622	CbGpPWpGaD
Sibutramine—Decreased appetite—Cisplatin—esophageal cancer	0.00119	0.00147	CcSEcCtD
Sibutramine—SLC6A3—NRF2 pathway—NFE2L2—esophageal cancer	0.00119	0.00621	CbGpPWpGaD
Sibutramine—Muscle spasms—Capecitabine—esophageal cancer	0.00119	0.00147	CcSEcCtD
Sibutramine—Pneumonia—Methotrexate—esophageal cancer	0.00119	0.00147	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00118	0.00146	CcSEcCtD
Sibutramine—Depression—Methotrexate—esophageal cancer	0.00118	0.00145	CcSEcCtD
Sibutramine—Pain—Cisplatin—esophageal cancer	0.00117	0.00145	CcSEcCtD
Sibutramine—Vision blurred—Capecitabine—esophageal cancer	0.00117	0.00144	CcSEcCtD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.00116	0.00608	CbGpPWpGaD
Sibutramine—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—esophageal cancer	0.00116	0.00607	CbGpPWpGaD
Sibutramine—Tremor—Capecitabine—esophageal cancer	0.00116	0.00143	CcSEcCtD
Sibutramine—Renal failure—Methotrexate—esophageal cancer	0.00116	0.00143	CcSEcCtD
Sibutramine—SLC6A2—NRF2 pathway—CYP2A6—esophageal cancer	0.00116	0.00603	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—SST—esophageal cancer	0.00115	0.00602	CbGpPWpGaD
Sibutramine—Stomatitis—Methotrexate—esophageal cancer	0.00115	0.00142	CcSEcCtD
Sibutramine—Ill-defined disorder—Capecitabine—esophageal cancer	0.00115	0.00142	CcSEcCtD
Sibutramine—Conjunctivitis—Methotrexate—esophageal cancer	0.00115	0.00142	CcSEcCtD
Sibutramine—Anaemia—Capecitabine—esophageal cancer	0.00114	0.00142	CcSEcCtD
Sibutramine—Sweating—Methotrexate—esophageal cancer	0.00113	0.0014	CcSEcCtD
Sibutramine—Feeling abnormal—Cisplatin—esophageal cancer	0.00113	0.0014	CcSEcCtD
Sibutramine—Haematuria—Methotrexate—esophageal cancer	0.00112	0.00139	CcSEcCtD
Sibutramine—Malaise—Capecitabine—esophageal cancer	0.00112	0.00138	CcSEcCtD
Sibutramine—Epistaxis—Methotrexate—esophageal cancer	0.00111	0.00138	CcSEcCtD
Sibutramine—Vertigo—Capecitabine—esophageal cancer	0.00111	0.00138	CcSEcCtD
Sibutramine—Syncope—Capecitabine—esophageal cancer	0.00111	0.00137	CcSEcCtD
Sibutramine—Leukopenia—Capecitabine—esophageal cancer	0.00111	0.00137	CcSEcCtD
Sibutramine—Palpitations—Capecitabine—esophageal cancer	0.00109	0.00135	CcSEcCtD
Sibutramine—Loss of consciousness—Capecitabine—esophageal cancer	0.00109	0.00135	CcSEcCtD
Sibutramine—Body temperature increased—Cisplatin—esophageal cancer	0.00108	0.00134	CcSEcCtD
Sibutramine—Cough—Capecitabine—esophageal cancer	0.00108	0.00134	CcSEcCtD
Sibutramine—Hypertension—Capecitabine—esophageal cancer	0.00107	0.00132	CcSEcCtD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.00106	0.00556	CbGpPWpGaD
Sibutramine—Haemoglobin—Methotrexate—esophageal cancer	0.00106	0.00132	CcSEcCtD
Sibutramine—Haemorrhage—Methotrexate—esophageal cancer	0.00106	0.00131	CcSEcCtD
Sibutramine—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.00106	0.00551	CbGpPWpGaD
Sibutramine—Myalgia—Capecitabine—esophageal cancer	0.00105	0.0013	CcSEcCtD
Sibutramine—Arthralgia—Capecitabine—esophageal cancer	0.00105	0.0013	CcSEcCtD
Sibutramine—Chest pain—Capecitabine—esophageal cancer	0.00105	0.0013	CcSEcCtD
Sibutramine—Pharyngitis—Methotrexate—esophageal cancer	0.00105	0.0013	CcSEcCtD
Sibutramine—Anxiety—Capecitabine—esophageal cancer	0.00105	0.0013	CcSEcCtD
Sibutramine—Discomfort—Capecitabine—esophageal cancer	0.00104	0.00129	CcSEcCtD
Sibutramine—Dry mouth—Capecitabine—esophageal cancer	0.00103	0.00127	CcSEcCtD
Sibutramine—SLC6A3—NRF2 pathway—CYP2A6—esophageal cancer	0.00102	0.00534	CbGpPWpGaD
Sibutramine—Visual impairment—Methotrexate—esophageal cancer	0.00102	0.00126	CcSEcCtD
Sibutramine—Confusional state—Capecitabine—esophageal cancer	0.00102	0.00126	CcSEcCtD
Sibutramine—Oedema—Capecitabine—esophageal cancer	0.00101	0.00125	CcSEcCtD
Sibutramine—Hypersensitivity—Cisplatin—esophageal cancer	0.00101	0.00125	CcSEcCtD
Sibutramine—Infection—Capecitabine—esophageal cancer	0.001	0.00124	CcSEcCtD
Sibutramine—Shock—Capecitabine—esophageal cancer	0.000994	0.00123	CcSEcCtD
Sibutramine—Eye disorder—Methotrexate—esophageal cancer	0.000989	0.00122	CcSEcCtD
Sibutramine—Thrombocytopenia—Capecitabine—esophageal cancer	0.000989	0.00122	CcSEcCtD
Sibutramine—Tinnitus—Methotrexate—esophageal cancer	0.000987	0.00122	CcSEcCtD
Sibutramine—Tachycardia—Capecitabine—esophageal cancer	0.000986	0.00122	CcSEcCtD
Sibutramine—Asthenia—Cisplatin—esophageal cancer	0.000983	0.00122	CcSEcCtD
Sibutramine—Skin disorder—Capecitabine—esophageal cancer	0.000981	0.00121	CcSEcCtD
Sibutramine—Hyperhidrosis—Capecitabine—esophageal cancer	0.000977	0.00121	CcSEcCtD
Sibutramine—Anorexia—Capecitabine—esophageal cancer	0.000963	0.00119	CcSEcCtD
Sibutramine—Angiopathy—Methotrexate—esophageal cancer	0.00096	0.00119	CcSEcCtD
Sibutramine—Immune system disorder—Methotrexate—esophageal cancer	0.000956	0.00118	CcSEcCtD
Sibutramine—Chills—Methotrexate—esophageal cancer	0.00095	0.00117	CcSEcCtD
Sibutramine—Hypotension—Capecitabine—esophageal cancer	0.000944	0.00117	CcSEcCtD
Sibutramine—SLC6A4—NRF2 pathway—TGFBR2—esophageal cancer	0.000942	0.00492	CbGpPWpGaD
Sibutramine—Diarrhoea—Cisplatin—esophageal cancer	0.000938	0.00116	CcSEcCtD
Sibutramine—Alopecia—Methotrexate—esophageal cancer	0.000935	0.00116	CcSEcCtD
Sibutramine—SLC6A4—NRF2 pathway—HMOX1—esophageal cancer	0.000929	0.00485	CbGpPWpGaD
Sibutramine—Malnutrition—Methotrexate—esophageal cancer	0.000922	0.00114	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00092	0.00114	CcSEcCtD
Sibutramine—SLC6A4—Circadian rythm related genes—GHRL—esophageal cancer	0.000917	0.00479	CbGpPWpGaD
Sibutramine—Insomnia—Capecitabine—esophageal cancer	0.000914	0.00113	CcSEcCtD
Sibutramine—Paraesthesia—Capecitabine—esophageal cancer	0.000907	0.00112	CcSEcCtD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—GNG7—esophageal cancer	0.000903	0.00471	CbGpPWpGaD
Sibutramine—Dysgeusia—Methotrexate—esophageal cancer	0.000902	0.00112	CcSEcCtD
Sibutramine—Dyspnoea—Capecitabine—esophageal cancer	0.000901	0.00111	CcSEcCtD
Sibutramine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.000896	0.00468	CbGpPWpGaD
Sibutramine—Back pain—Methotrexate—esophageal cancer	0.000891	0.0011	CcSEcCtD
Sibutramine—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.000891	0.00465	CbGpPWpGaD
Sibutramine—Dyspepsia—Capecitabine—esophageal cancer	0.000889	0.0011	CcSEcCtD
Sibutramine—CYP3A4—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.000884	0.00462	CbGpPWpGaD
Sibutramine—Decreased appetite—Capecitabine—esophageal cancer	0.000878	0.00109	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000872	0.00108	CcSEcCtD
Sibutramine—Vomiting—Cisplatin—esophageal cancer	0.000871	0.00108	CcSEcCtD
Sibutramine—Vision blurred—Methotrexate—esophageal cancer	0.000868	0.00107	CcSEcCtD
Sibutramine—Rash—Cisplatin—esophageal cancer	0.000864	0.00107	CcSEcCtD
Sibutramine—Pain—Capecitabine—esophageal cancer	0.000864	0.00107	CcSEcCtD
Sibutramine—Constipation—Capecitabine—esophageal cancer	0.000864	0.00107	CcSEcCtD
Sibutramine—Dermatitis—Cisplatin—esophageal cancer	0.000863	0.00107	CcSEcCtD
Sibutramine—Ill-defined disorder—Methotrexate—esophageal cancer	0.000855	0.00106	CcSEcCtD
Sibutramine—Anaemia—Methotrexate—esophageal cancer	0.000852	0.00105	CcSEcCtD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—ALDH2—esophageal cancer	0.000846	0.00442	CbGpPWpGaD
Sibutramine—CYP3A4—Tryptophan metabolism—ALDH2—esophageal cancer	0.00084	0.00438	CbGpPWpGaD
Sibutramine—Feeling abnormal—Capecitabine—esophageal cancer	0.000833	0.00103	CcSEcCtD
Sibutramine—Malaise—Methotrexate—esophageal cancer	0.000831	0.00103	CcSEcCtD
Sibutramine—Vertigo—Methotrexate—esophageal cancer	0.000828	0.00102	CcSEcCtD
Sibutramine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000826	0.00102	CcSEcCtD
Sibutramine—Leukopenia—Methotrexate—esophageal cancer	0.000825	0.00102	CcSEcCtD
Sibutramine—Nausea—Cisplatin—esophageal cancer	0.000814	0.00101	CcSEcCtD
Sibutramine—SLC6A2—NRF2 pathway—TGFBR2—esophageal cancer	0.00081	0.00423	CbGpPWpGaD
Sibutramine—Cough—Methotrexate—esophageal cancer	0.000804	0.000995	CcSEcCtD
Sibutramine—Urticaria—Capecitabine—esophageal cancer	0.000803	0.000993	CcSEcCtD
Sibutramine—SLC6A2—NRF2 pathway—HMOX1—esophageal cancer	0.000799	0.00417	CbGpPWpGaD
Sibutramine—Abdominal pain—Capecitabine—esophageal cancer	0.000799	0.000988	CcSEcCtD
Sibutramine—Body temperature increased—Capecitabine—esophageal cancer	0.000799	0.000988	CcSEcCtD
Sibutramine—Convulsion—Methotrexate—esophageal cancer	0.000798	0.000988	CcSEcCtD
Sibutramine—Arthralgia—Methotrexate—esophageal cancer	0.000785	0.00097	CcSEcCtD
Sibutramine—Myalgia—Methotrexate—esophageal cancer	0.000785	0.00097	CcSEcCtD
Sibutramine—Chest pain—Methotrexate—esophageal cancer	0.000785	0.00097	CcSEcCtD
Sibutramine—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000781	0.00408	CbGpPWpGaD
Sibutramine—Discomfort—Methotrexate—esophageal cancer	0.000775	0.000959	CcSEcCtD
Sibutramine—Confusional state—Methotrexate—esophageal cancer	0.000758	0.000938	CcSEcCtD
Sibutramine—Anaphylactic shock—Methotrexate—esophageal cancer	0.000752	0.00093	CcSEcCtD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000749	0.00391	CbGpPWpGaD
Sibutramine—Infection—Methotrexate—esophageal cancer	0.000747	0.000924	CcSEcCtD
Sibutramine—Hypersensitivity—Capecitabine—esophageal cancer	0.000744	0.000921	CcSEcCtD
Sibutramine—Thrombocytopenia—Methotrexate—esophageal cancer	0.000736	0.000911	CcSEcCtD
Sibutramine—Skin disorder—Methotrexate—esophageal cancer	0.000731	0.000904	CcSEcCtD
Sibutramine—Hyperhidrosis—Methotrexate—esophageal cancer	0.000727	0.000899	CcSEcCtD
Sibutramine—CYP3A4—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000726	0.00379	CbGpPWpGaD
Sibutramine—Asthenia—Capecitabine—esophageal cancer	0.000725	0.000897	CcSEcCtD
Sibutramine—SLC6A3—NRF2 pathway—TGFBR2—esophageal cancer	0.000718	0.00375	CbGpPWpGaD
Sibutramine—Anorexia—Methotrexate—esophageal cancer	0.000717	0.000887	CcSEcCtD
Sibutramine—Pruritus—Capecitabine—esophageal cancer	0.000715	0.000884	CcSEcCtD
Sibutramine—SLC6A3—NRF2 pathway—HMOX1—esophageal cancer	0.000708	0.00369	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000704	0.00368	CbGpPWpGaD
Sibutramine—Hypotension—Methotrexate—esophageal cancer	0.000703	0.000869	CcSEcCtD
Sibutramine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000701	0.00366	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—HIF1A—esophageal cancer	0.000692	0.00361	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—GNG7—esophageal cancer	0.000692	0.00361	CbGpPWpGaD
Sibutramine—Diarrhoea—Capecitabine—esophageal cancer	0.000691	0.000855	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000685	0.000848	CcSEcCtD
Sibutramine—Insomnia—Methotrexate—esophageal cancer	0.00068	0.000841	CcSEcCtD
Sibutramine—Paraesthesia—Methotrexate—esophageal cancer	0.000675	0.000835	CcSEcCtD
Sibutramine—Dyspnoea—Methotrexate—esophageal cancer	0.000671	0.000829	CcSEcCtD
Sibutramine—Somnolence—Methotrexate—esophageal cancer	0.000669	0.000827	CcSEcCtD
Sibutramine—Dizziness—Capecitabine—esophageal cancer	0.000668	0.000826	CcSEcCtD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000668	0.00349	CbGpPWpGaD
Sibutramine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000668	0.00348	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000664	0.00346	CbGpPWpGaD
Sibutramine—Dyspepsia—Methotrexate—esophageal cancer	0.000662	0.000819	CcSEcCtD
Sibutramine—Decreased appetite—Methotrexate—esophageal cancer	0.000654	0.000809	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000649	0.000803	CcSEcCtD
Sibutramine—SLC6A3—Neuronal System—ALDH2—esophageal cancer	0.000648	0.00338	CbGpPWpGaD
Sibutramine—Pain—Methotrexate—esophageal cancer	0.000643	0.000796	CcSEcCtD
Sibutramine—Vomiting—Capecitabine—esophageal cancer	0.000642	0.000795	CcSEcCtD
Sibutramine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000638	0.00333	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000637	0.00333	CbGpPWpGaD
Sibutramine—Rash—Capecitabine—esophageal cancer	0.000637	0.000788	CcSEcCtD
Sibutramine—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	0.000637	0.00332	CbGpPWpGaD
Sibutramine—Dermatitis—Capecitabine—esophageal cancer	0.000636	0.000787	CcSEcCtD
Sibutramine—Headache—Capecitabine—esophageal cancer	0.000633	0.000783	CcSEcCtD
Sibutramine—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.00063	0.00329	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000624	0.00326	CbGpPWpGaD
Sibutramine—Feeling abnormal—Methotrexate—esophageal cancer	0.00062	0.000767	CcSEcCtD
Sibutramine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000615	0.000761	CcSEcCtD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000611	0.00319	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000611	0.00319	CbGpPWpGaD
Sibutramine—Nausea—Capecitabine—esophageal cancer	0.0006	0.000742	CcSEcCtD
Sibutramine—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.000598	0.00312	CbGpPWpGaD
Sibutramine—Urticaria—Methotrexate—esophageal cancer	0.000597	0.000739	CcSEcCtD
Sibutramine—Body temperature increased—Methotrexate—esophageal cancer	0.000595	0.000735	CcSEcCtD
Sibutramine—Abdominal pain—Methotrexate—esophageal cancer	0.000595	0.000735	CcSEcCtD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000592	0.00309	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.000565	0.00295	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000564	0.00295	CbGpPWpGaD
Sibutramine—Hypersensitivity—Methotrexate—esophageal cancer	0.000554	0.000685	CcSEcCtD
Sibutramine—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000551	0.00287	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000541	0.00282	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000541	0.00282	CbGpPWpGaD
Sibutramine—Asthenia—Methotrexate—esophageal cancer	0.00054	0.000667	CcSEcCtD
Sibutramine—Pruritus—Methotrexate—esophageal cancer	0.000532	0.000658	CcSEcCtD
Sibutramine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000518	0.0027	CbGpPWpGaD
Sibutramine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000515	0.00269	CbGpPWpGaD
Sibutramine—Diarrhoea—Methotrexate—esophageal cancer	0.000515	0.000637	CcSEcCtD
Sibutramine—SLC6A4—Circadian rythm related genes—NOS2—esophageal cancer	0.000514	0.00268	CbGpPWpGaD
Sibutramine—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000508	0.00265	CbGpPWpGaD
Sibutramine—Dizziness—Methotrexate—esophageal cancer	0.000497	0.000615	CcSEcCtD
Sibutramine—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000491	0.00256	CbGpPWpGaD
Sibutramine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000484	0.00253	CbGpPWpGaD
Sibutramine—Vomiting—Methotrexate—esophageal cancer	0.000478	0.000592	CcSEcCtD
Sibutramine—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000478	0.00249	CbGpPWpGaD
Sibutramine—Rash—Methotrexate—esophageal cancer	0.000474	0.000587	CcSEcCtD
Sibutramine—Dermatitis—Methotrexate—esophageal cancer	0.000474	0.000586	CcSEcCtD
Sibutramine—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000473	0.00247	CbGpPWpGaD
Sibutramine—Headache—Methotrexate—esophageal cancer	0.000471	0.000583	CcSEcCtD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.000463	0.00242	CbGpPWpGaD
Sibutramine—Nausea—Methotrexate—esophageal cancer	0.000447	0.000553	CcSEcCtD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.00042	0.00219	CbGpPWpGaD
Sibutramine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000417	0.00218	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000415	0.00217	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.00041	0.00214	CbGpPWpGaD
Sibutramine—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000392	0.00205	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.000386	0.00201	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.000385	0.00201	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000381	0.00199	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000372	0.00194	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000359	0.00187	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000354	0.00185	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—EP300—esophageal cancer	0.000314	0.00164	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000292	0.00153	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000278	0.00145	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.000275	0.00144	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000261	0.00136	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000256	0.00134	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000246	0.00128	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000227	0.00118	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—TP53—esophageal cancer	0.000225	0.00117	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000222	0.00116	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000219	0.00114	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000218	0.00114	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000208	0.00109	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000206	0.00107	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000164	0.000857	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000145	0.000759	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.000112	0.000584	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.000112	0.000584	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CA1—esophageal cancer	9.52e-05	0.000497	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—SLC10A2—esophageal cancer	9.52e-05	0.000497	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CA2—esophageal cancer	8.71e-05	0.000455	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PLCE1—esophageal cancer	8.09e-05	0.000423	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ADH7—esophageal cancer	8.09e-05	0.000423	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ADH1B—esophageal cancer	7.1e-05	0.000371	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—TYMP—esophageal cancer	6.78e-05	0.000354	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CYP26A1—esophageal cancer	6.6e-05	0.000344	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ALOX15—esophageal cancer	6.43e-05	0.000336	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GSTO1—esophageal cancer	6.13e-05	0.00032	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—TPI1—esophageal cancer	6.13e-05	0.00032	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ALDOB—esophageal cancer	5.88e-05	0.000307	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GAPDH—esophageal cancer	5.66e-05	0.000296	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CRABP1—esophageal cancer	5.61e-05	0.000293	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GNG7—esophageal cancer	5.34e-05	0.000279	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ALDH2—esophageal cancer	5e-05	0.000261	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GSTT1—esophageal cancer	4.76e-05	0.000248	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CYP2A6—esophageal cancer	4.7e-05	0.000245	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PTGS1—esophageal cancer	4.46e-05	0.000233	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ENO1—esophageal cancer	4.46e-05	0.000233	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PSME2—esophageal cancer	4.39e-05	0.000229	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PSME1—esophageal cancer	4.39e-05	0.000229	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CYP1B1—esophageal cancer	3.79e-05	0.000198	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CYP19A1—esophageal cancer	3.56e-05	0.000186	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—HMOX1—esophageal cancer	3.25e-05	0.00017	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ABCB1—esophageal cancer	3.12e-05	0.000163	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CREBBP—esophageal cancer	2.09e-05	0.000109	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—NOS3—esophageal cancer	1.87e-05	9.75e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.71e-05	8.92e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—EP300—esophageal cancer	1.42e-05	7.42e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.05e-05	5.49e-05	CbGpPWpGaD
